Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

calcium

CAL-500

calcium (CAL-500) is an FDA-listed pharmaceutical active ingredient. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 20
Pipeline programs 95
News articles 0
Drug details — calcium
US status
approved
Class
—
Route
INJECTION
Patents
20
Programs
95
Data quality
0.84
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

calcium (CAL-500) is an FDA-listed pharmaceutical active ingredient. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN calcium
Brand CAL-500
Route INJECTION
Formulation INJECTABLE
Originator Lacuna Pharma Pty Ltd

Approval history

Authority Status Date
FDA approved —
TGA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. 20210081 Phase 3 · Amgen · Colorectal Cancer (CRC)
  2. A021502 Phase 3 · George Institute for · stage III colon adenocarcinoma with deficient MMR
  3. APHP200073 Phase 3 · PARItec · Erythema multiforme (EM) in its severe form managed at the h
  4. APHP211429 Phase 3 · PARItec · patients suffering from acute myocarditis confirmed on Cardi
  5. APHP220917 Phase 3 · PARItec · patient with colorectal cancer with hepatic metastasis
  6. AZP-3601-CLI-002 Phase 3 · Alexion Europe SAS · Hypoparathyroidism
  7. C3651021 Phase 3 · First Biotech (Australia) · Cancer cachexia
  8. C4221015 Phase 3 · First Biotech (Australia) · Colorectal cancer (BRAF V600E-mutant mCRC)

Related patents

Browse patents Lacuna Pharma Pty Ltd patent hub

  1. WO 2026082899

    ARN POUR LA PREVENTION OU LE TRAITEMENT DE LA TUBERCULOSE

    Expires Wed Apr 18 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026068864

    DOMAINES CH1 ET CL MODIFIÉS POUR LA PRÉVENTION DU MÉSAPPARIEMENT DE CHAÎNE

    Expires Wed Mar 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2026062193

    COMPOSITIONS ET PROCÉDÉS

    Expires Wed Mar 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2026057625

    PEPTIDOGLYCANE HYDROLASES AYANT UN DOMAINE CHAP AVEC SITE ACTIF MODIFIÉ

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2026057626

    PEPTIDOGLYCANE HYDROLASES AYANT DE MULTIPLES DOMAINES ENZYMATIQUEMENT ACTIFS

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2026058153

    UTILISATIONS DE RÉCEPTEUR DE LYMPHOCYTES T DE VPH-16 ET COMPOSITIONS ASSOCIÉES

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2026047601

    RÉCEPTEURS DE LYMPHOCYTES T (TCR)

    Expires Wed Feb 28 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. WO 2026033380

    PROCESSUS DE PRÉPARATION DE COMPLEXES OLIGOSACCHARIDIQUES

    Expires Wed Feb 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2026027695

    COMPOSITIONS ET PROCÉDÉS

    Expires Wed Jan 31 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2026021698

    PARTICULE D'ACIDE NUCLÉIQUE

    Expires Wed Jan 24 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2026015857

    COMPOSITION DE VACCIN DESTINÉE À DÉCLENCHER UNE RÉPONSE DES LYMPHOCYTES T CD8+ SPÉCIFIQUE DE L'EBV

    Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. WO 2026013643

    PROCÉDÉS ET COMPOSITIONS POUR CONCEVOIR DES CHAÎNES D'ÉPITOPES AVEC DES LIEURS

    Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2025264662

    COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UN MÉLANOME

    Expires Thu Dec 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2025261607

    PARTICULES, COMPOSITIONS ET PROCÉDÉS

    Expires Thu Dec 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12410170

    2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12384773

    Thiazole compounds and methods of use thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12351609

    Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12257224

    Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12202832

    Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12186306

    Methods of treatment for cystic fibrosis

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is calcium?

calcium (CAL-500) is an FDA-listed pharmaceutical active ingredient. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for calcium?

CAL-500 is a marketed brand name for calcium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of calcium?

calcium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.